3028213-52-4
Chemical Structure
Mal-Exatecan
- CAS No.: 3028213-52-4
- Formula:C34H33FN4O7
- Molecular Weight:628.65
InChIKey: JEMWLPJRYDSDGD-HUBRWUETSA-N
SMILES: O=C(C=CC1=O)N1CCCCCC(N[C@@H]2C3=C4C(C(N5C4)=CC([C@](O)(C(OC6)=O)CC)=C6C5=O)=NC7=CC(F)=C(C)C(CC2)=C73)=O
Biological Activity: Mal-Exatecan is a maleimide (Mal)-modified Exatecan (HY-13631) and is a DNA topoisomerase I (topoisomerase I) inhibitor. Mal-Exatecan serves as a cytotoxic payload for antibody-drug conjugates (ADCs), conjugating to antibody cysteine residues via the maleimide group and releasing Exatecan within tumor cells to exert cytotoxic effects. Mal-Exatecan can be used for ADC construction and cancer-related research[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mal-Exatecan | 99.39% | Mal-Exatecan is a maleimide (Mal)-modified Exatecan (HY-13631) and is a DNA topoisomerase I (topoisomerase I) inhibitor. Mal-Exatecan serves as a cytotoxic payload for antibody-drug conjugates (ADCs), conjugating to antibody cysteine residues via the maleimide group and releasing Exatecan within tumor cells to exert cytotoxic effects. Mal-Exatecan can be used for ADC construction and cancer-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.84
HY-13631GExatecan analog 13 -
Similarity Score 0.81
HY-128995Glycyl-Exatecan -
Similarity Score 0.81
HY-13631DDXd -
Similarity Score 0.81
HY-13631K(1R,9S)-Dxd -
Similarity Score 0.80
HY-160543Exatecan-amide-CH2-O-CH2-CH2-OH -
Similarity Score 0.79
HY-128979Deruxtecan analog 2 -
Similarity Score 0.79
HY-43565Exatecan intermediate 9 -
Similarity Score 0.79
HY-79490Ac-Exatecan -
Similarity Score 0.78
HY-153891Deruxtecan 2-hydroxypropanamide -
Explore the MedChemAI to find more analogs
References
- [1]. Sun FX, Tohgo A, Bouvet M, Yagi S, Nassirpour R, Moossa AR, Hoffman RM. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003 Jan 1;63(1):80-5. [Content Brief]
- [2]. Jo U, et al. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular cancer therapeutics. 2022 Jul 05;21(7):1090-1102.
